Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Monkeypox
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-1850
      • TNX-801
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Chronic Migraine and Major Depressive Disorder. Please visit Clinical Trials.

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Tonix in the News
  • Press Releases
  • IR Events
  • Email Alerts
  • Op-Eds
May 28, 2014 2:26pm EDT

Tonix Pharmaceuticals to be Added to the MSCI Global Micro Cap Index

May 20, 2014 8:40am EDT

Tonix Pharmaceuticals to Present at the MIXiii Biomed Conference in Israel

May 13, 2014 5:00pm EDT

Tonix Pharmaceuticals Reports First Quarter 2014 Financial Results

May 12, 2014 8:40am EDT

Tonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia

Apr 9, 2014 8:40am EDT

Tonix Pharmaceuticals Spotlighted in April 7 Issue of BioCentury

Apr 1, 2014 8:45am EDT

Tonix Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Regulatory Affairs

Mar 31, 2014 9:15am EDT

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results

Mar 5, 2014 8:20am EST

Tonix Pharmaceuticals to Present at the ROTH Conference

Mar 3, 2014 9:35am EST

Tonix Pharmaceuticals Completes Pre-IND Meeting With FDA on TNX-201 for Episodic Tension-Type Headache: Clinical Development to Begin in 4Q 2014

Feb 21, 2014 8:20am EST

Tonix Pharmaceuticals Spotlighted in Three Media Outlets in February

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 41
  • Page 42
  • Page 43
  • Page 44
  • Page 45
  • Page 46
  • Page 47
  • Page 48
  • Page 49
  • Page 50
  • …
  • …Page 53
  • Next Pagearrow_forward
rss_feed News RSS
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.